Time for costly medicine monopolies to go from TPP trade talks

Source: Conversation.com |November 9, 2017

Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.

The latest plan to get the controversial trade deal up and running again after the withdrawal of the United States involves freezing some of its controversial rules. These include rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis. Continue reading

Advertisements
Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

Patient groups march for access to medicines in South Africa

Source: MSF Access
Finalise the draft policy and amend laws to save lives, activists tell dti
PRETORIA – Today, more than 1,000 members of the Fix the Patent Laws Coalition (FTPL) will march to the Department of Trade and Industry (dti) in support of the government’s efforts to fix our patent laws and ensure everyone has access to the medicines they need.
Made up of 36 patient groups and civil society organisations representing people affected by most major diseases in South Africa, the FTPL Coalition will hand over its in-depth submission in support of the draft Intellectual Property Policy, and a new report documenting the dire inaccessibility of many cancer medicines due to patent barriers. The draft policy was released by the dti in August 2017.

Continue reading

Posted in Uncategorized | Leave a comment

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

Source: Bloomberg

Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.

 The Initiative for Medicines, Access & Knowledge, a nonprofit focused on how patents affect access to medicine, said that it’s filed petitions with the U.S. Patent Trial and Appeal Board seeking to challenge intellectual-property rights that would keep generic versions of Sovaldi from entering the market.

Continue reading

Posted in Cancer, Evergreening, Hepatitis C, Patent, Uncategorized | Leave a comment

Greek health minister takes issue with Roche’s withdrawal of cancer medicine due to mandatory, retroactive discount

Source: EndPoints News

Drug prices are not just a US problem. Greece’s minister of health on Tuesday expressed dismay over Roche’s decision to withdraw a cancer medicine because of a new mandatory discount imposed by the country.

Greek health minister Andreas Xanthos called the move by Switzerland-based Roche “unacceptable” and said citizens’ access to innovative medicines should not be a business decision, according to a translation of a statement released Tuesday. Continue reading

Posted in Cancer, Compulsory Licensing, Patent, TRIPS, Uncategorized | Leave a comment

Access to affordable stents and other medical devices – Indian Government should reject the bullying tactics of the US based medical device industry

The US based medical devices industry through the Advanced Medical Technology Association (AdvaMed) has approached the US Trade Representative (USTR) with a demand to partially or fully suspend or withdraw India’s benefits under the Generalized System of Preferences (GSP). This is a barefaced attempt to intimidate the Indian Government and retaliate against its decision to fix the retail prices of cardiovascular stents and knee implants in the public interest.

This issue is supposed to be discussed at the US India Trade Policy Forum to be held in Washington DC on 26th October i.e. Tomorrow. Against this background please find the press statement from the All India Drug Action Network (AIDAN). Continue reading

Posted in Uncategorized, US Pressure, USTR | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint

India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines

South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is likely to inhibit competition in countries like India. Photo: Hemant Mishra/Mint

South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is likely to inhibit competition in countries like India. Photo: Hemant Mishra/Mint

Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world.

Courtesy- ajp.com.auCourtesy- ajp.com.au

As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, Korea, the international medical humanitarian organization Médecins Sans Frontières (MSF) is appealing to Korea and Japan to withdraw proposals that could hinder global access to affordable generic medicines and life-saving vaccines. Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment